Kaplan lecture 2023: lymphopenia in particle therapy

References

• [IAEA] International Atomic Energy Agency. 2011. Cytogenetic dosimetry : applications in preparedness for and response to radiation emergencies. Manual Series. Vienna: International Atomic Energy Agency.
   Google Scholar
• Abuodeh Y, Venkat P, Kim S. 2016. Systematic review of case reports on the abscopal effect. Curr Probl Cancer. 40(1):25–37. doi:10.1016/j.currproblcancer.2015.10.001
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, et al. 2018. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 379(24):2342–2350. doi:10.1056/NEJMoa1809697
   PubMed Web of Science ®Google Scholar
• Barendsen GW. 1979. Influence of radiation quality on the effectiveness of small doses for induction of reproductive death and chromosome aberrations in mammalian cells. Int J Radiat Biol Relat Stud Phys Chem Med. 36(1):49–63. doi:10.1080/09553007914550811
   PubMed Web of Science ®Google Scholar
• Bedford JS, Mitchell JB, Griggs HG, Bender MA. 1978. Radiation-induced cellular reproductive death and chromosome aberrations. Radiat Res. 76(3):573–586.
   PubMed Web of Science ®Google Scholar
• Boustani J, Grapin M, Laurent P-A, Apetoh L, Mirjolet C. 2019. The 6th R of radiobiology: reactivation of anti-tumor immune response. Cancers (Basel). 11(6):860. doi:10.3390/cancers11060860
   PubMed Web of Science ®Google Scholar
• Campbell AC, Hersey P, MacLennan ICM, Kay HEM, Pike MC. 1973. Immunosuppressive consequences of radiotherapy and chemotherapy in patients with acute lymphoblastic leukaemia. Br Med J. 2(5863):385–388. doi:10.1136/bmj.2.5863.385
   PubMedGoogle Scholar
• Cavalieri S, Vitolo V, Barcellini A, Ronchi S, Facoetti A, Campo C, Klersy C, Molinelli S, Agustoni F, Ferretti VV, et al. 2023. Immune checkpoint inhibitors and Carbon iON radiotherapy in solid Cancers with stable disease (ICONIC). Future Oncol. 19(3):193–203. doi:10.2217/fon-2022-0503
   PubMed Web of Science ®Google Scholar
• Cella L, Monti S, Pacelli R, Palma G. 2024. Modeling frameworks for radiation induced lymphopenia: a critical review. Radiother Oncol. 190:110041. doi:10.1016/j.radonc.2023.110041
   PubMed Web of Science ®Google Scholar
• Chamoto K, Yaguchi T, Tajima M, Honjo T. 2023. Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1. Nat Rev Immunol. 23(10):682–695. doi:10.1038/s41577-023-00867-9
   PubMed Web of Science ®Google Scholar
• Chang JY, Lin SH, Dong W, Liao Z, Gandhi SJ, Gay CM, Zhang J, Chun SG, Elamin YY, Fossella FV, et al. 2023. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet. 402(10405):871–881. doi:10.1016/S0140-6736(23)01384-3
   PubMed Web of Science ®Google Scholar
• Chen D, Verma V, Patel RR, Barsoumian HB, Cortez MA, Welsh JW. 2020. Absolute lymphocyte count predicts abscopal responses and outcomes in patients receiving combined immunotherapy and radiation therapy: analysis of 3 phase 1/2 trials. Int J Radiat Oncol Biol Phys. 108(1):196–203. doi:10.1016/j.ijrobp.2020.01.032
   PubMed Web of Science ®Google Scholar
• Cho Y, Kim Y, Chamseddine I, Lee WH, Kim HR, Lee IJ, Hong MH, Cho BC, Lee CG, Cho S, et al. 2022. Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapy. Radiother Oncol. 168:1–7. doi:10.1016/j.radonc.2022.01.007
   PubMed Web of Science ®Google Scholar
• Cornforth MN, Bedford JS. 1993. Ionizing radiation damage and its early development in chromosomes. Adv Radiat Biol. 17:423–496. doi:10.1016/B978-0-12-035417-7.50010-6
   Google Scholar
• Cortiula F, Hendriks LEL, Wijsman R, Houben R, Steens M, Debakker S, Canters R, Trovò M, Sijtsema NM, Niezink AGH, et al. 2024. Proton and photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and adjuvant immune therapy. Radiother Oncol. 190:110019. doi:10.1016/j.radonc.2023.110019
   PubMed Web of Science ®Google Scholar
• d’Alesio V, Pacelli R, Durante M, Canale Cama G, Cella L, Gialanella G, Grossi G, Pugliese M, Punzo G, Sardi I, et al. 2003. Lymph nodes in the irradiated field influence the yield of radiation-induced chromosomal aberrations in lymphocytes from breast cancer patients. Int J Radiat Oncol Biol Phys. 57(3):732–738., doi:10.1016/S0360-3016(03)00664-3
   PubMed Web of Science ®Google Scholar
• Dai D, Tian Q, Yu G, Shui Y, Jiang H, Wei Q. 2022. Severe radiation-induced lymphopenia affects the outcomes of esophageal cancer: a comprehensive systematic review and meta-analysis. Cancers (Basel). 14(12):3024. doi:10.3390/cancers14123024
   PubMed Web of Science ®Google Scholar
• Damen PJJ, Kroese TE, van Hillegersberg R, Schuit E, Peters M, Verhoeff JJC, Lin SH, van Rossum PSN. 2021. The influence of severe radiation-induced lymphopenia on overall survival in solid tumors: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 111(4):936–948. doi:10.1016/j.ijrobp.2021.07.1695
   PubMed Web of Science ®Google Scholar
• De B, Ng SP, Liu AY, Avila S, Tao R, Holliday EB, Brownlee Z, Kaseb A, Lee S, Raghav K, et al. 2021. Radiation-associated lymphopenia and outcomes of patients with unresectable hepatocellular carcinoma treated with radiotherapy. J Hepatocell Carcinoma. 8:57–69. doi:10.2147/JHC.S282062
   PubMed Web of Science ®Google Scholar
• de Kermenguy F, Meziani L, Mondini M, Clémenson C, Morel D, Deutsch E, Robert C. 2023. Radio-induced lymphopenia in the era of anti-cancer immunotherapy. Int Rev Cell Mol Biol. 378:1–30. doi:10.1016/bs.ircmb.2023.03.002
   PubMedGoogle Scholar
• Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, Formenti SC. 2004. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 58(3):862–870. doi:10.1016/j.ijrobp.2003.09.012
   PubMed Web of Science ®Google Scholar
• Dewey WC, Miller HH, Leeper DB. 1971. Chromosomal aberrations and mortality of x-irradiated mammalian cells: emphasis on repair. Proc Natl Acad Sci U S A. 68(3):667–671. doi:10.1073/pnas.68.3.667
   PubMed Web of Science ®Google Scholar
• Di Giorgio M, Edwards AA, Moquet JE, Finnon P, Hone PA, Lloyd DC, Kreiner AJ, Schuff JA, Taja MR, Vallerga MB, et al. 2004. Chromosome aberrations induced in human lymphocytes by heavy charged particles in track segment mode. Radiat Prot Dosimetry. 108(1):47–53. doi:10.1093/rpd/nch012
   PubMed Web of Science ®Google Scholar
• Durante M. 2005. Biomarkers of space radiation risk. Radiat Res. 164(4 Pt 2):467–473. doi:10.1667/rr3359.1
   PubMed Web of Science ®Google Scholar
• Durante M, Bedford JS, Chen DJ, Conrad S, Cornforth MN, Natarajan AT, van Gent DC, Obe G. 2013. From DNA damage to chromosome aberrations: Joining the break. Mutat Res. 756(1-2):5–13. doi:10.1016/j.mrgentox.2013.05.014
   PubMed Web of Science ®Google Scholar
• Durante M, Bonassi S, George K, Cucinotta FA. 2001. Risk estimation based on chromosomal aberrations induced by radiation. Radiat Res. 156(5 Pt 2):662–667. doi:10.1667/0033-7587(2001)156[0662:reboca[PMC]2.0.co;2]
   PubMed Web of Science ®Google Scholar
• Durante M, Brenner DJ, Formenti SC. 2016. Does heavy ion therapy work through the immune system? Int J Radiat Oncol Biol Phys. 96(5):934–936. doi:10.1016/j.ijrobp.2016.08.037
   PubMed Web of Science ®Google Scholar
• Durante M, Cucinotta FA. 2008. Heavy ion carcinogenesis and human space exploration. Nat Rev Cancer. 8(6):465–472. doi:10.1038/nrc2391
   PubMed Web of Science ®Google Scholar
• Durante M, Debus J, Loeffler JS. 2021. Physics and biomedical challenges of cancer therapy with accelerated heavy ions. Nat Rev Phys. 3(12):777–790. doi:10.1038/s42254-021-00368-5
   PubMedGoogle Scholar
• Durante M, Formenti S. 2020. Harnessing radiation to improve immunotherapy: better with particles? Br J Radiol. 93(1107):20190224. doi:10.1259/bjr.20190224
   PubMed Web of Science ®Google Scholar
• Durante M, Furusawa Y, Gotoh E. 1998. A simple method for simultaneous interphase-metaphase chromosome analysis in biodosimetry. Int J Radiat Biol. 74(4):457–462. doi:10.1080/095530098141320
   PubMed Web of Science ®Google Scholar
• Durante M, Golubev A, Park W-Y, Trautmann C. 2019. Applied nuclear physics at the new high-energy particle accelerator facilities. Phys Rep. 800:1–37. doi:10.1016/j.physrep.2019.01.004
   Google Scholar
• Durante M, Paganetti H. 2016. Nuclear physics in particle therapy : a review. Rep Prog Phys. 79(9):096702. doi:10.1088/0034-4885/79/9/096702
   PubMed Web of Science ®Google Scholar
• Durante M, Yamada S, Ando K, Furusawa Y, Kawata T, Majima H, Nakano T, Tsujii H. 2000. X-rays vs. carbon-ion tumor therapy: cytogenetic damage in lymphocytes. Int J Radiat Oncol Biol Phys. 47(3):793–798. doi:10.1016/S0360-3016(00)00455-7
   PubMed Web of Science ®Google Scholar
• Durante M, Yamada S, Ando K, Furusawa Y, Kawata T, Majima H, Nakano T, Tsujii H. 1999. Measurements of the equivalent whole-body dose during radiation therapy by cytogenetic methods. Phys Med Biol. 44(5):1289–1298. doi:10.1088/0031-9155/44/5/314
   PubMed Web of Science ®Google Scholar
• El Houat Y, Massard C, Quillien V, de Crevoisier R, Castelli J. 2023. Meta-analysis and critical review: association between radio-induced lymphopenia and overall survival in solid cancers. Adv Radiat Oncol. 8(2):101038. doi:10.1016/j.adro.2022.101038
   PubMedGoogle Scholar
• Formenti SC, Demaria S. 2013. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 105(4):256–265. doi:10.1093/jnci/djs629
   PubMed Web of Science ®Google Scholar
• Formenti SC, Demaria S. 2009. Systemic effects of local radiotherapy. Lancet Oncol. 10(7):718–726. doi:10.1016/S1470-2045(09)70082-8
   PubMed Web of Science ®Google Scholar
• Friedes C, Iocolano M, Lee SH, Duan L, Li B, Doucette A, Cohen RB, Aggarwal C, Sun LL, Levin WP, et al. 2024. The effective radiation dose to immune cells predicts lymphopenia and inferior cancer control in locally advanced NSCLC. Radiother Oncol. 190:110030. doi:10.1016/j.radonc.2023.110030
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Aryankalayil MJ, Coleman CN, Formenti SC. 2023. Emerging evidence for adapting radiotherapy to immunotherapy. Nat Rev Clin Oncol. 20(8):543–557. doi:10.1038/s41571-023-00782-x
   PubMed Web of Science ®Google Scholar
• George K, Durante M, Willingham V, Wu H, Yang TC, Cucinotta F. a 2003. Biological effectiveness of accelerated particles for the induction of chromosome damage measured in metaphase and interphase human lymphocytes. Radiat Res. 160(4):425–435. doi:10.1667/RR3064
   PubMed Web of Science ®Google Scholar
• Gotoh E, Durante M. 2006. Chromosome condensation outside of mitosis: mechanisms and new tools. J Cell Physiol. 209(2):297–304. doi:10.1002/jcp.20720
   PubMed Web of Science ®Google Scholar
• Harrison JD, Balonov M, Bochud F, Martin C, Menzel H-G, Ortiz-Lopez P, Smith-Bindman R, Simmonds JR, Wakeford R. 2021. ICRP publication 147: use of dose quantities in radiological protection. Ann ICRP. 50(1):9–82. doi:10.1177/0146645320911864
   PubMedGoogle Scholar
• Hartel C, Nikoghosyan A, Durante M, Sommer S, Nasonova E, Fournier C, Lee R, Debus J, Schulz-Ertner D, Ritter S. 2010. Chromosomal aberrations in peripheral blood lymphocytes of prostate cancer patients treated with IMRT and carbon ions. Radiother Oncol. 95(1):73–78. doi:10.1016/j.radonc.2009.08.031
   PubMed Web of Science ®Google Scholar
• Helm A, Fournier C, Durante M. 2022. Particle radiotherapy and molecular therapies: mechanisms and strategies towards clinical applications. Expert Rev Mol Med. 24:e8. doi:10.1017/erm.2022.2
   PubMed Web of Science ®Google Scholar
• Helm A, Totis C, Durante M, Fournier C. 2023. Are charged particles a good match for combination with immunotherapy? Current knowledge and perspectives. Int Rev Cell Mol Biol. 376:1–36. doi:10.1016/bs.ircmb.2023.01.001
   PubMedGoogle Scholar
• Hsieh RC-E, Lee C-H, Huang H-C, Wu S-W, Chou C-Y, Hung S-P, Lee C-W, Krishnan S, Venkatesulu BP, Lee J-C, et al. 2023. Clinical and dosimetric results of proton or photon radiation therapy for large (>5 cm) hepatocellular carcinoma: a retrospective analysis. Int J Radiat Oncol. doi:10.1016/j.ijrobp.2023.09.049
   Google Scholar
• Iorio GC, Spieler BO, Ricardi U, Dal Pra A. 2021. The impact of pelvic nodal radiotherapy on hematologic toxicity: a systematic review with focus on leukopenia, lymphopenia and future perspectives in prostate cancer treatment. Crit Rev Oncol Hematol. 168:103497. doi:10.1016/j.critrevonc.2021.103497
   PubMed Web of Science ®Google Scholar
• Kamada T, Tsujii H, Blakely EA, Debus J, De Neve W, Durante M, Jäkel O, Mayer R, Orecchia R, Pötter R, et al. 2015. Carbon ion radiotherapy in Japan: an assessment of 20 years of clinical experience. Lancet Oncol. 16(2):e93–e100. doi:10.1016/S1470-2045(14)70412-7
   PubMed Web of Science ®Google Scholar
• Kawashiro S, Yamada S, Okamoto M, Ohno T, Nakano T, Shinoto M, Shioyama Y, Nemoto K, Isozaki Y, Tsuji H, et al. 2018. Multi-institutional STUDY OF CARBON-ION RADIOTHERAPY FOR LOCALLY ADVANCED PANCREATIC CANCEr: Japan Carbon-ion Radiation Oncology Study Group (J-CROS) Study 1403 pancreas. Int J Radiat Oncol Biol Phys. 101(5):1212–1221. doi:10.1016/j.ijrobp.2018.04.057
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lièvre A, et al. 2021. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 384(13):1191–1203. doi:10.1056/NEJMoa2032125
   PubMed Web of Science ®Google Scholar
• Kim H, Park S, Jung HA, Lee S-H, Park K, Ahn YC, Oh D, Ahn M-J. 2023. Phase II trial of combined durvalumab plus tremelimumab with proton therapy for recurrent or metastatic head and neck squamous cell carcinoma. Cancer Res Treat. 55(4):1104–1112. doi:10.4143/crt.2023.502
   PubMed Web of Science ®Google Scholar
• Kim N, Myoung Noh J, Lee W, Park B, Park H, Young Park J, Pyo H. 2021. Proton beam therapy reduces the risk of severe radiation-induced lymphopenia during chemoradiotherapy for locally advanced non-small cell lung cancer: a comparative analysis of proton versus photon therapy. Radiother Oncol. 156:166–173. doi:10.1016/j.radonc.2020.12.019
   PubMed Web of Science ®Google Scholar
• Kim S, Byun HK, Shin J, Lee IJ, Sung W. 2023. Normal tissue complication probability modeling of severe radiation-induced lymphopenia using blood dose for hepatocellular carcinoma patients. Int J Radiat Oncol. 89:100889. doi:10.1016/j.ijrobp.2023.11.060
   Google Scholar
• Kim Y, Chamseddine I, Cho Y, Kim JS, Mohan R, Shusharina N, Paganetti H, Lin S, Yoon HI, Cho S, et al. 2023. Neural network based ensemble model to predict radiation induced lymphopenia after concurrent chemo-radiotherapy for non-small cell lung cancer from two institutions. Neoplasia. 39:100889. doi:10.1016/j.neo.2023.100889
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Butterfield LH, Tarhini A. a, Zarour H, Kalinski P, Ferrone S. 2012. Immunotherapy of cancer in 2012. CA Cancer J Clin. 62(5):309–335. doi:10.3322/caac.20132
   PubMed Web of Science ®Google Scholar
• Lee NY, Ferris RL, Psyrri A, Haddad RI, Tahara M, Bourhis J, Harrington K, Chang PM-H, Lin J-C, Razaq MA, et al. 2021. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 22(4):450–462. doi:10.1016/S1470-2045(20)30737-3
   PubMed Web of Science ®Google Scholar
• Lee R, Yamada S, Yamamoto N, Miyamoto T, Ando K, Durante M, Tsujii H. 2004. Chromosomal aberrations in lymphocytes of lung cancer patients treated with carbon ions. J Radiat Res. 45(2):195–199. doi:10.1269/jrr.45.195
   PubMed Web of Science ®Google Scholar
• Li Y, Fan X, Yu Q, Zhai H, Mo M, Sun J, Mi J, Lu R, Mao J, Chen J, et al. 2023. Proton and carbon ion radiation therapy decreased severe lymphopenia by reducing thoracic vertebra and aortic doses in non-small cell lung cancer versus intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 116(3):579–589. doi:10.1016/j.ijrobp.2022.12.030
   PubMed Web of Science ®Google Scholar
• Lim M, Weller M, Idbaih A, Steinbach J, Finocchiaro G, Raval RR, Ansstas G, Baehring J, Taylor JW, Honnorat J, et al. 2022. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro Oncol. 24(11):1935–1949. doi:10.1093/neuonc/noac116
   PubMed Web of Science ®Google Scholar
• Mohan R, Liu AY, Brown PD, Mahajan A, Dinh J, Chung C, McAvoy S, McAleer MF, Lin SH, Li J, et al. 2020. Proton therapy reduces the likelihood of high-grade radiation–induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons. Neuro Oncol. 23(2):284–294. doi:10.1093/neuonc/noaa182
   Web of Science ®Google Scholar
• Nikoghosyan AV, Schulz-Ertner D, Herfarth K, Didinger B, Münter MW, Jensen AD, Jäkel O, Hoess A, Haberer T, Debus J. 2011. Acute toxicity of combined photon IMRT and carbon ion boost for intermediate-risk prostate cancer – acute toxicity of 12C for PC. Acta Oncol. 50(6):784–790. doi:10.3109/0284186X.2011.584558
   PubMed Web of Science ®Google Scholar
• Noda K, Furukawa T, Fujimoto T, Hara Y, Inaniwa T, Iwata Y, Katagiri K, Kanematsu N, Mizushima K, Mori S, et al. 2017. Recent progress and future plans of heavy-ion cancer radiotherapy with HIMAC. Nucl Instrum Methods Phys Res Sect B Beam Interact Mater Atoms. 406:374–378. doi:10.1016/j.nimb.2017.04.021
   Web of Science ®Google Scholar
• Pignalosa D, Lee R, Hartel C, Sommer S, Nikoghosyan A, Debus J, Ritter S, Durante M. 2013. Chromosome inversions in lymphocytes of prostate cancer patients treated with X-rays and carbon ions. Radiother Oncol. 109(2):256–261. doi:10.1016/j.radonc.2013.09.021
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, et al. 2012. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 366(10):925–931. doi:10.1056/NEJMoa1112824
   PubMed Web of Science ®Google Scholar
• Rajeev-Kumar G, Pitroda SP. 2023. Synergizing radiotherapy and immunotherapy: current challenges and strategies for optimization. Neoplasia. 36:100867. doi:10.1016/j.neo.2022.100867
   PubMed Web of Science ®Google Scholar
• Ritter S, Nasonova E, Gudowska-Nowak E, Scholz M, Kraft G. 2002. Integrated chromosome aberration yields determined for V79 cells after high LET radiation. Int J Radiat Biol. 78(11):1063–1064. doi:10.1080/0955300021000020292
   PubMedGoogle Scholar
• Routman DM, Garant A, Lester SC, Day CN, Harmsen WS, Sanheuza CT, Yoon HH, Neben-Wittich MA, Martenson JA, Haddock MG, et al. 2019. A comparison of grade 4 lymphopenia with proton versus photon radiation therapy for esophageal cancer. Adv Radiat Oncol. 4(1):63–69. doi:10.1016/j.adro.2018.09.004
   PubMedGoogle Scholar
• Schoenfeld JD, Giobbie-Hurder A, Ranasinghe S, Kao KZ, Lako A, Tsuji J, Liu Y, Brennick RC, Gentzler RD, Lee C, et al. 2022. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 23(2):279–291. doi:10.1016/S1470-2045(21)00658-6
   PubMed Web of Science ®Google Scholar
• Sender R, Weiss Y, Navon Y, Milo I, Azulay N, Keren L, Fuchs S, Ben-Zvi D, Noor E, Milo R. 2023. The total mass, number, and distribution of immune cells in the human body. Proc Natl Acad Sci USA. 120(44):e2308511120. doi:10.1073/pnas.2308511120
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. 2015. The future of immune checkpoint therapy. Science. 348(6230):56–61. doi:10.1126/science.aaa8172
   PubMed Web of Science ®Google Scholar
• Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, Liu J, Subudhi SK, Poon C, Gant KL, et al. 2023. Immune checkpoint therapy—current perspectives and future directions. Cell. 186(8):1652–1669. doi:10.1016/j.cell.2023.03.006
   PubMed Web of Science ®Google Scholar
• Sherry AD, von Eyben R, Newman NB, Gutkin P, Mayer I, Horst K, Chakravarthy AB, Rafat M. 2020. Systemic inflammation after radiation predicts locoregional recurrence, progression, and mortality in stage II–III triple-negative breast cancer. Int J Radiat Oncol Biol Phys. 108(1):268–276. doi:10.1016/j.ijrobp.2019.11.398
   PubMed Web of Science ®Google Scholar
• Shiraishi Y, Fang P, Xu C, Song J, Krishnan S, Koay EJ, Mehran RJ, Hofstetter WL, Blum-Murphy M, Ajani JA, et al. 2018. Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: a propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. Radiother Oncol. 128(1):154–160. doi:10.1016/j.radonc.2017.11.028
   PubMed Web of Science ®Google Scholar
• Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, Vansteenkiste JF, Garassino MC, Hui R, Quantin X, et al. 2022. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. J Clin Oncol. 40(12):1301–1311. doi:10.1200/JCO.21.01308
   PubMed Web of Science ®Google Scholar
• Stjernswärd J, Vánky F, Jondal M, Wigzell H, Sealy R. 1972. Lymphopenia and change in distribution of human B and T lymphocytes in peripheral blood induced by irradiation of mammary carcinoma. Lancet. 1(7765):1352–1356. doi:10.1016/S0140-6736(72)91091-4
   PubMed Web of Science ®Google Scholar
• Sumiya T, Ishikawa H, Hiroshima Y, Nakamura M, Murakami M, Mizumoto M, Okumura T, Sakurai H. 2021. The impact of lymphopenia during chemoradiotherapy using photons or protons on the clinical outcomes of esophageal cancer patients. J Radiat Res. 62:1045–1055. doi:10.1093/jrr/rrab094
   PubMed Web of Science ®Google Scholar
• Takanen S, Bottero M, Nisticò P, Sanguineti G. 2022. A systematic review on the impact of hypofractionated and stereotactic radiotherapy on immune cell subpopulations in cancer patients. Cancers (Basel). 14(21):5190. doi:10.3390/cancers14215190
   PubMed Web of Science ®Google Scholar
• Takeda K, Umezawa R, Yamamoto T, Takahashi N, Suzuki Y, Kishida K, Omata S, Jingu K. 2023. Acute hematologic toxicity of radiation therapy – a comprehensive analysis and predictive nomogram. J Radiat Res. 64(6):954–961. doi:10.1093/jrr/rrad069
   PubMed Web of Science ®Google Scholar
• Tao Y, Biau J, Sun XS, Sire C, Martin L, Alfonsi M, Prevost JB, Modesto A, Lafond C, Tourani JM, et al. 2023. Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial. Ann Oncol. 34(1):101–110. doi:10.1016/j.annonc.2022.10.006
   PubMed Web of Science ®Google Scholar
• Terrones-Campos C, Ledergerber B, Vogelius IR, Helleberg M, Specht L, Lundgren J. 2021. Hematological toxicity in patients with solid malignant tumors treated with radiation – Temporal analysis, dose response and impact on survival. Radiother Oncol. 158:175–183. doi:10.1016/j.radonc.2021.02.029
   PubMed Web of Science ®Google Scholar
• Upadhaya S, Neftelinov ST, Hodge J, Campbell J. 2022. Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape. Nat Rev Drug Discov. 21(7):482–483. doi:10.1038/d41573-022-00030-4
   PubMed Web of Science ®Google Scholar
• van Rossum PSN, Juan-Cruz C, Stam B, Rossi MMG, Lin SH, Abravan A, Belderbos JSA, Sonke J-J. 2023. Severe radiation-induced lymphopenia during concurrent chemoradiotherapy for stage III non-small cell lung cancer: external validation of two prediction models. Front Oncol. 13:1278723. doi:10.3389/fonc.2023.1278723
   PubMed Web of Science ®Google Scholar
• Venkatesulu B, Giridhar P, Pujari L, Chou B, Lee JH, Block AM, Upadhyay R, Welsh JS, Harkenrider MM, Krishnan S, et al. 2022. Lymphocyte sparing normal tissue effects in the clinic (LymphoTEC): a systematic review of dose constraint considerations to mitigate radiation-related lymphopenia in the era of immunotherapy. Radiother Oncol. 177:81–94. doi:10.1016/j.radonc.2022.10.019
   PubMed Web of Science ®Google Scholar
• Wang X, van Rossum PSN, Chu Y, Hobbs BP, Grassberger C, Hong TS, Liao Z, Yang J, Zhang X, Netherton T, et al. 2023. Severe lymphopenia during chemoradiation therapy for esophageal cancer: comprehensive analysis of randomized phase 2B trial of proton beam therapy versus intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 118(2):368–377. doi:10.1016/j.ijrobp.2023.08.058
   PubMed Web of Science ®Google Scholar
• Wu H, Durante M, George K, Yang TC. 1997. Induction of chromosome aberrations in human cells by charged particles. Radiat Res. 148(5 Suppl):S102–S7.
   PubMed Web of Science ®Google Scholar
• Yamada S, Durante M, Ando K, Furusawa Y, Kawata T, Majima H, Tsujii H. 2000. Complex-type chromosomal exchanges in blood lymphocytes during radiation therapy correlate with acute toxicity. Cancer Lett. 150(2):215–221. doi:10.1016/S0304-3835(99)00405-X
   PubMed Web of Science ®Google Scholar
• Yang G, Yoon HI, Lee J, Kim J, Kim H, Cho J, Lee CG, Chang JS, Cho Y, Kim JS, et al. 2023. Risk of on-treatment lymphopenia is associated with treatment outcome and efficacy of consolidation immunotherapy in patients with non-small cell lung cancer treated with concurrent chemoradiotherapy. Radiother Oncol. 189:109934. doi:10.1016/j.radonc.2023.109934
   PubMed Web of Science ®Google Scholar
• Yang TC, George K, Johnson AS, Durante M, Fedorenko BS. 1997. Biodosimetry results from space flight Mir-18. Radiat Res. 148(5 Suppl):S17–S23.
   PubMed Web of Science ®Google Scholar
• Yovino S, Kleinberg L, Grossman SA, Narayanan M, Ford E. 2013. The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells. Cancer Invest. 31(2):140–144. doi:10.3109/07357907.2012.762780
   PubMed Web of Science ®Google Scholar
• Zhang Y, Huang C, Li S. 2023. Influence of treatment-related lymphopenia on the efficacy of immune checkpoint inhibitors in lung cancer: a meta-analysis. Front Oncol. 13:1287555. doi:10.3389/fonc.2023.1287555
   PubMedGoogle Scholar